May 7th, 2024

Here's RMR1 update #14!

The survival curves continue to provide tantalising but preliminary information. Particularly exciting is how long the all-control group took, measured from the start of the study, to reach the survival percentage that the all-treatment group is currently at (namely 45% for females and 65% for males): we can look at the ratio of the two in order to ask how well the combination is working.

As of now, for females it's (973 - 578) / (816 - 578) = 1.66, and for males it's (973-578)/(841-578) = 1.50. (See the dotted lines that I've added to the graphs.) So that's not the effect size that I've defined as "robust mouse rejuvenation", which is a ratio of 2, but it's a good deal better than any other study I know of.

The message - and again, I know it's only preliminary - is that RMR1 is confirming the two fundamental beliefs that motivate this research program: first, that combo rejuvenation has greater potential than any other longevity approach, and second, that it's hugely important to do more of these studies, starting with the one whose design we announced a few months ago.

We are still struggling to raise the funds for that study; I'm devoutly hoping that the ongoing success of RMR1 will change that soon.